Clinical Usefulness of a Mobile Application for the Appropriate Selection of the Antiarrhythmic Device in Heart Failure

Appropriate selection of implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device can be challenging in patients with left ventricular (LV) dysfunction. In this setting, limited information exists about the role of medical applications in helping physicians to choose the most useful device.

[1]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[2]  D. Rowland,et al.  Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. , 2012, American heart journal.

[3]  H. White,et al.  Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. , 2005, Journal of the American College of Cardiology.

[4]  Robert Furberg,et al.  Social Media: Opportunities for Quality Improvement and Lessons for Providers—A Networked Model for Patient-Centered Care Through Digital Engagement , 2014, Current Cardiology Reports.

[5]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[6]  David O. Martin,et al.  Cardiac Resynchronization Therapy in Non‐Left Bundle Branch Block Morphologies , 2009, Pacing and clinical electrophysiology : PACE.

[7]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[8]  Wojciech Zareba,et al.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. , 2002, The New England journal of medicine.

[9]  Luigi Tavazzi,et al.  Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. , 2002, American heart journal.

[10]  P. Ellinor,et al.  Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study). , 2015, The American journal of cardiology.

[11]  Cevat Kirma,et al.  Do Mobile Phones Pose a Potential Risk to Autonomic Modulation of the Heart? , 2011, Pacing and clinical electrophysiology : PACE.

[12]  H. Krum,et al.  Medical therapy versus implantable cardioverter -defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of > 35,000 patients. , 2014, International journal of cardiology.

[13]  Eric J. Topol,et al.  The emerging field of mobile health , 2015, Science Translational Medicine.

[14]  D. Exner,et al.  Prior Coronary Artery Bypass Surgery and Risk of Death Among Patients With Ischemic Left Ventricular Dysfunction , 2001, Circulation.

[15]  A. Moss,et al.  Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. , 2006, Journal of the American College of Cardiology.

[16]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[17]  K. Ellenbogen,et al.  Resynchronization Therapy for the Treatment of Heart Failure , 2003, Circulation.

[18]  Mark A Hlatky,et al.  2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2013, Circulation.

[19]  A. Badreldin,et al.  Third‐Generation Mobile Phones (UMTS) Do Not Interfere with Permanent Implanted Pacemakers , 2010, Pacing and clinical electrophysiology : PACE.

[20]  Bristow.  Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) : Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure , 2004 .

[21]  W. Maisel,et al.  Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. , 2003, The American journal of cardiology.

[22]  J. Udell,et al.  Comparable benefit of β-blocker therapy in heart failure across regions of the world: meta-analysis of randomized clinical trials. , 2014, The Canadian journal of cardiology.

[23]  Eric Fain,et al.  Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. , 2004, The New England journal of medicine.

[24]  J. Udell,et al.  Abstract 10963: Comparable Benefit of Beta-Blocker Therapy in Heart Failure across Regions of the World: Meta-Analysis of Randomized Clinical Trials , 2013 .

[25]  Andrea Mazzanti,et al.  [2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death]. , 2015, Kardiologia polska.